We provide you with 20 years of free, institutional-grade data for FDMT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of FDMT. Explore the full financial landscape of FDMT stock.
| Reported Date | CIK | Ticker | Type |
|---|
4D Molecular Therapeutics, Inc(NASDAQ:FDMT) 
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has t...
Founded: 2013
CEO: David Kirn
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about FDMT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.